SCHEMBL22010526

SCHEMBL22010526

COC(=O)C(Cc1ccccc1)CS(=O)(=O)N[Si](C)(C)C(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.44
▸ KMT2A Q03164 4/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ CA12 O43570 2/20 0.42
▸ CA7 P43166 2/20 0.42
▸ CA9 Q16790 2/20 0.42
▸ CA14 Q9ULX7 2/20 0.42
▸ CA2 P00918 1/20 0.42
▸ FOLH1 Q04609 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ ITGA4 P13612 1/20 0.39
▸ ITGB7 P26010 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ THRB P10828 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25829681 0.81 KMT2A (0.49) POLBKMT2AMEN1CA12CA7
SCHEMBL7269972 0.80 POLB (0.48) POLBKMT2AMEN1CA12CA7
SCHEMBL22010524 0.79 KMT2A (0.46) POLBKMT2AMEN1CA12CA7
SCHEMBL21962937 0.78 KMT2A (0.51) POLBKMT2AMEN1CA12CA7
SCHEMBL21962922 0.77 KMT2A (0.57) POLBKMT2AMEN1CA12CA7
SCHEMBL7332197 0.77 KMT2A (0.50) POLBKMT2AMEN1CA12CA7
SCHEMBL7335528 0.77 KMT2A (0.50) POLBKMT2AMEN1CA12CA7
SCHEMBL7415092 0.76 KMT2A (0.52) POLBKMT2AMEN1CA12CA7
SCHEMBL7335530 0.76 MEN1 (0.49) POLBKMT2AMEN1CA12CA7
SCHEMBL8710569 0.75 FOLH1 (0.43) POLBKMT2AMEN1FOLH1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230024859-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2023-01-26 — — US disclosed
WO-2020102100-A9 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2022-01-06 — — WO disclosed
WO-2020102100-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS INFLAMMASOME RESEARCH, INC. (US) 2020-05-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230024859-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NLRP1, NLRP3, NOD1 POLB 4622/4885KMT2A 4433/4885MEN1 3418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback